Mampaso F, Sanchez-Madrid F, Marcen R, Molina A, Pascual J, Bricio T, Martin A, Alvarez V
Department of Pathology, Hospital Ramon y Cajal, Madrid, Spain.
Transplantation. 1993 Sep;56(3):687-91. doi: 10.1097/00007890-199309000-00035.
We have studied in thirty renal biopsies (from 30 cadaver allograft patients) the expression of both LFA-1 and VLA-4 leukocyte adhesion receptors and their respective ICAM-1 and VCAM-1 endothelial cell ligands, during early allograft dysfunction (24 +/- 5 days after transplantation), reversed either by antirejection therapy (n = 14) or by reduction in CsA dose (n = 16). We have found that the levels of expression of the integrin VLA-4 and the activation signal AIM/CD69 (activation inducer molecule) on interstitial cells were significantly (P < 0.001) higher in rejection than in nephrotoxicity. A main differential expression pattern was observed for VCAM-1, the endothelial cell ligand of VLA-4. Interestingly, a strong staining pattern of the renal vascular endothelium and 35% of tubular epithelium was obtained with anti-VCAM-1 antibody in rejection, as compared with a weak reactivity in endothelium and discrete staining pattern on tubules in nephrotoxicity. On the other hand, we found that the mean percentage of infiltrating cells bearing LFA-1 molecules and the intensity of ICAM-1 (a LFA-1 ligand) expression on endothelium were closely similar in both rejection and CsA nephrotoxicity. Nevertheless, a discrete significant (P < 0.05) "de novo" expression of ICAM-1 was present on tubular cells during rejection. Our results strongly suggest that in rejection the interstitial cell infiltrate seems to be facilitated by the contribution of both LFA-1/ICAM-1 and VLA-4/VCAM-1 cell adhesion mechanisms, and also that VLA-4/VCAM-1 leukocyte interaction does not play a role in cases with CsA nephrotoxicity. Furthermore, the differential expression patterns of VLA-4 and VCAM-1 molecules found between rejection and CsA nephrotoxicity could provide valuable immunohistochemical criteria in the diagnosis of allograft dysfunction.
我们研究了30例肾活检标本(取自30例尸体同种异体肾移植患者),观察在移植早期肾功能不全(移植后24±5天)时,LFA-1和VLA-4白细胞黏附受体及其各自的内皮细胞配体ICAM-1和VCAM-1的表达情况。这些患者的移植肾功能不全通过抗排斥治疗(n = 14)或降低环孢素A(CsA)剂量(n = 16)得以逆转。我们发现,与肾毒性相比,排斥反应时间质细胞上整合素VLA-4的表达水平以及激活信号AIM/CD69(激活诱导分子)显著更高(P < 0.001)。观察到VLA-4的内皮细胞配体VCAM-1有主要的差异表达模式。有趣的是,与肾毒性时内皮细胞反应较弱及肾小管上离散的染色模式相比,抗VCAM-1抗体在排斥反应中可使肾血管内皮和35%的肾小管上皮呈现强染色模式。另一方面,我们发现,排斥反应和CsA肾毒性时,携带LFA-1分子的浸润细胞的平均百分比以及内皮细胞上ICAM-1(LFA-1的配体)表达强度非常相似。然而,在排斥反应期间,肾小管细胞上存在离散的显著(P < 0.05)ICAM-1“从头”表达。我们的结果强烈表明,在排斥反应中,LFA-1/ICAM-1和VLA-4/VCAM-1细胞黏附机制共同作用似乎促进了间质细胞浸润,并且VLA-4/VCAM-1白细胞相互作用在CsA肾毒性病例中不起作用。此外,排斥反应和CsA肾毒性之间发现的VLA-4和VCAM-1分子的差异表达模式可为同种异体移植肾功能不全的诊断提供有价值的免疫组织化学标准。